In a research report released Monday, Roth Capital analyst Debjit Chattopadhyay initiated coverage on Agios Pharmaceuticals (NASDAQ:AGIO) with a Neutral rating and a price …
In a research report published Monday, Roth Capital analyst Debjit Chattopadhyay reiterated a Buy rating on bluebird bio (NASDAQ:BLUE) and raised his price …
Roth Capital analyst Debjit Chattopadhyay reiterated a Buy rating on Cell Therapeutics (NASDAQ:CTIC) with a $4.50 price target, which implies an upside of …
In a research report sent to investors today, Roth Capital analyst Debjit Chattopadhyay reiterated a Buy rating on NeoGenomics Inc. (NASDAQ:NEO) with a …
In a research report sent to investors today, Roth Capital analyst Debjit Chattopadhyay maintained a Buy rating on Nektar Therapeutics (NASDAQ:NKTR) with a …
Roth Capital analyst Debjit Chattopadhyay reiterated a Buy rating on Nektar Therapeutics (NASDAQ:NKTR) with a$21 price target, following the news that NKTR’s partner Baxter International …
In a research report published Monday, Roth Capital analyst Debjit Chattopadhyay reiterated a Buy rating on Sarepta Therapeutics (NASDAQ:SRPT) with a price target …
In a research report issued today, Roth Capital analyst Debjit Chattopadhyay maintained a Buy rating on Nektar Therapeutics (NASDAQ:NKTR) with a $21 price …
Roth Capital analyst Debjit Chattopadhyay downgraded shares of Prosensa Holding (NASDAQ:RNA) to Neutral with a price target of $17.75, following the news that Biomarin (NASDAQ:BMRN) will acquire …
In a research report sent to investors today, Roth Capital analyst Debjit Chattopadhyay maintained a Buy rating on Sarepta Therapeutics Inc. (NASDAQ:SRPT) with …
